Navigation Links
Labopharm Comments on Recent Trading Activity
Date:12/12/2008

LAVAL, QC, Dec. 12 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS, NASDAQ: DDSS), at the request of Market Surveillance on behalf of the Toronto Stock Exchange, today commented on the recent trading activity of its common shares. The Company is not aware of any reason for the recent trading activity other than the approaching Prescription Drug User Fee Act (PDUFA) action date for its once-daily formulation of tramadol, by which the U.S. Food and Drug Administration (FDA) could provide final approval for marketing and sale of the formulation in the United States. The PDUFA action date is January 2, 2009. The Company has not yet received any decision from the FDA. When it does, it will issue a press release.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
2. Labopharms NDA for Novel Trazodone Formulation accepted for review by FDA
3. Labopharm announces change to Board of Directors
4. Labopharm Reports Results for Third Quarter Fiscal 2008
5. Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)
6. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
7. Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET)
8. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
9. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
10. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
11. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... ... Engineering (ISPE) will host its 2017 Process Validation and Process Validation ... offer comprehensive solutions to process validation lifecycle challenges faced by process validation ...
(Date:7/26/2017)... ... 2017 , ... A global center of excellence specializing in ... of the art center will provide advanced surgical care (heart surgery), management of ... patients longer lives. , North American Veterinary Heart Center, the “Heart Center,” will ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... innovative specialty pharmacies, has released an updated version of the HCV Treatment Path ... for treating chronic hepatitis C virus (HCV) infection. All of the latest HCV ...
(Date:7/25/2017)... ... 25, 2017 , ... Creative Pharmacist and ... the Pharmacist eCare Plan to Computer-Rx pharmacies through the STRAND platform. ... to develop the Pharmacist eCare Plan, a shared document detailing a patient’s current ...
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Gina Negrette, a ... more than a decade of experience in psychiatry, treating clients in diverse settings, ... eating disorders, psychotic and manic conditions, as well as those who were fighting ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... The Institute for In Vitro Sciences (IIVS), ... of a VITROCELL® inhalation exposure system thanks to a ... device, which is designed to replace animals in inhalation ... to airborne test materials in an environment that mimics ... for testing combustible tobacco products, as well as next ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston ... and unparalleled access to global decision makers and innovative ... 800+ life science leaders during two impactful days. BioPharm ... provides delegates with additional networking opportunities with 4,500+ life ...
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of Diplomat ... families to thrive on nutrition support. To celebrate its anniversary, ... site has a fresh new look with improved organization to create the ... ... "We,ve ...
Breaking Medicine Technology: